Kiya Abdisa Gurmessa

Dr. Kiya Abdisa Gurmessa


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
RVRashmi Venkatesh
Rashmi Venkatesh
AHAndrew S Huang
Andrew S Huang
KGKiya Abdisa Gurmessa
Kiya Abdisa Gurmessa
EHEdbert Hsu
Edbert Hsu
Background: Direct-acting antiviral agents (DAAs) have significantly reduced Hepatitis C Virus (HCV) transmission and improved health outcomes since their FDA approval in 2011. Despite these advances, over 70 million people remain untreated globally, with a disproportionately high burden in low- and middle-income countries (LMICs). Methods: Through a structured search of open access informational sources and an informal peer-reviewed literature review, HCV treatment barriers were identified, compiled, and analyzed. Current challenges to HCV treatment were organized by themes and summarized as recommendations for LMICs. Results: Key obstacles to HCV treatment in LMICs are identified, with the underdiagnosis and undertreatment of the disease linked to inadequate funding and healthcare infrastructure for screening and testing, poor awareness among healthcare providers, and the misinformation and stigmatization of HCV disease. Discussion: Recommendations for LMICs to attenuate treatment obstacles include distributing educational media, implementing mobile clinics, and fostering international partnerships. The successful implementation of these interventions has been demonstrated in developed countries. Conclusions: To achieve the WHO’s goal of eliminating HCV as a public health threat by 2030, concerted efforts are needed by LMICs to reduce gaps in care and ensure that all patients are afforded access to testing and treatment.